Thus far, the Major Depressive Disorder (MDD) specifier lineup has included some unsavory characters. As if these haven't been difficult enough, there is also the possibility of MDD patients ...

No difference seen across outcomes compared with serial midazolam infusions. HealthDay News — Serial adjunctive ketamine infusions are not more effective than serial midazolam infusions in reducing ...

Patients with major depressive disorder, including those who have not responded to first-line antidepressants, may benefit from short-term nitrous oxide treatment, a major meta-analysis led by the ...

This is a syndicated post stub. Clinical Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical ...

The use of 42 mg lumateperone combined with antidepressant therapy was linked to significantly reduced severity of depression and anxiety, as well as greater response and remission rates, and was ...

Patients who experienced a formulary-related rejection of cariprazine for adjunctive treatment of major depressive disorder had significantly higher hospitalization rates than those with approved ...

Please provide your email address to receive an email when new articles are posted on . At day 43, lumateperone led to greater improvement vs. placebo on all metrics. Treatment-emergent adverse events ...

NEW YORK, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ...

The researchers found that 19.2% of adolescents experienced major depressive episodes, but only 47.5% received treatment within the past year. HealthDay News — Few teens with depression receive ...

Major depressive episodes among US adolescents decreased significantly from 2021 to 2024, a new study shows — but disparities ...